Lyell Immunopharma (LYEL) EBIT (2020 - 2026)

Lyell Immunopharma has reported EBIT for 7 years, with the latest figure at -$44.3 million in Q1 2026.

• Quarterly EBIT rose 22.85% year-over-year to -$44.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$256.3 million (up 28.91% YoY) and the FY2025 annual result came in at -$269.4 million, up 24.91% from the prior year.
• EBIT advanced to -$44.3 million in Q1 2026 per LYEL's latest filing, from -$127.6 million in the prior quarter.
• Over five years, EBIT peaked at -$14.8 million in Q4 2022 and troughed at -$201.1 million in Q4 2024.
• A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2023: EBIT soared 68.9% in 2022, then plunged 302.52% in 2023.
• Over 5 years, EBIT stood at -$14.8 million in 2022, then slumped by 302.52% to -$59.5 million in 2023, then plunged by 238.02% to -$201.1 million in 2024, then soared by 36.54% to -$127.6 million in 2025, then surged by 65.32% to -$44.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$44.3 million, -$127.6 million, and -$37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.